Patents by Inventor Nathan J. SHARKEY

Nathan J. SHARKEY has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • PD-L1-SPECIFIC ANTIBODIES AND METHODS OF USING THE SAME
    Publication number: 20240150468
    Abstract: The present disclosure relates generally to antibodies and functional binding fragments thereof that bind to programmed death-ligand 1 (PD-L1). In particular, the disclosed antibodies and fragments bind to human PD-L1 and comprise novel complementary determining regions (CDRs) also disclosed herein. Finally, the present disclosure relates to administering the disclosed antibodies and fragments to subjects with cancer, thereby treating or slowing the progression or proliferation of the cancer.
    Type: Application
    Filed: October 6, 2023
    Publication date: May 9, 2024
    Applicant: Checkpoint Therapeutics, Inc.
    Inventors: Jonathan BELK, Nathan J. SHARKEY, Leonid GORELIK
  • ALK7 Binding Proteins and Uses Thereof
    Publication number: 20170306028
    Abstract: This disclosure provides ALK7-binding proteins such as anti-ALK7 antibodies, and compositions and methods for making the ALK7-binding proteins. In certain embodiments the ALK7-binding proteins inhibit, or antagonize ALK7 activity. In addition, the disclosure provides compositions and methods for diagnosing and treating overweight, obesity, diabetes, overweight, obesity, type 2 diabetes, and their associated conditions; metabolic disorders, and other diseases or conditions that can be treated, prevented or ameliorated by targeting ALK7.
    Type: Application
    Filed: April 21, 2017
    Publication date: October 26, 2017
    Applicants: Acceleron Pharma Inc., Adimab, LLC
    Inventors: John KNOPF, Jonathan BELK, Nathan J. SHARKEY, Ravindra KUMAR, Asya GRINBERG, Dianne SAKO, Roselyne CASTONGUAY, Yossi DAGON